These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Inclusion body myositis: clinical and pathological boundaries. Amato AA; Gronseth GS; Jackson CE; Wolfe GI; Katz JS; Bryan WW; Barohn RJ Ann Neurol; 1996 Oct; 40(4):581-6. PubMed ID: 8871577 [TBL] [Abstract][Full Text] [Related]
5. Update on the use of intravenous immune globulin in the treatment of patients with inflammatory muscle disease. Dalakas MC J Clin Immunol; 1995 Nov; 15(6 Suppl):70S-75S. PubMed ID: 8613495 [TBL] [Abstract][Full Text] [Related]
6. [The practice guideline 'Dermatomyositis, polymyositis and sporadic inclusion body myositis']. Hoogendijk JE; Bijlsma JW; van Engelen BG; Lindeman E; van Royen-Kerkhof A; de Rie MA; de Visser M; Jennekens FG; Ned Tijdschr Geneeskd; 2005 Sep; 149(38):2104-11. PubMed ID: 16201600 [TBL] [Abstract][Full Text] [Related]
7. [Current therapy for polymyositis and dermatomyositis]. Chérin P Rev Med Interne; 2008 Jun; 29 Spec No 2():9-14. PubMed ID: 18927983 [TBL] [Abstract][Full Text] [Related]
8. [Polymyositis, dermatomyositis and inclusion body myositis, nosological aspects]. Eymard B Presse Med; 2003 Oct; 32(35):1656-67. PubMed ID: 14631270 [TBL] [Abstract][Full Text] [Related]
9. [Polymyositis/dermatomyositis--clinical picture and treatment]. Anić B; Cerovec M Reumatizam; 2012; 59(2):44-50. PubMed ID: 23745455 [TBL] [Abstract][Full Text] [Related]
10. Corticosteroids in Myositis and Scleroderma. Postolova A; Chen JK; Chung L Rheum Dis Clin North Am; 2016 Feb; 42(1):103-18, ix. PubMed ID: 26611554 [TBL] [Abstract][Full Text] [Related]
11. Inflammatory myopathies: evaluation and management. Greenberg SA Semin Neurol; 2008 Apr; 28(2):241-9. PubMed ID: 18351525 [TBL] [Abstract][Full Text] [Related]
14. Current Classification and Management of Inflammatory Myopathies. Schmidt J J Neuromuscul Dis; 2018; 5(2):109-129. PubMed ID: 29865091 [TBL] [Abstract][Full Text] [Related]
15. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Dalakas MC Curr Opin Neurol; 2004 Oct; 17(5):561-7. PubMed ID: 15367860 [TBL] [Abstract][Full Text] [Related]
16. 64th ENMC International Workshop: therapeutic approaches to dermatomyositis, polymyositis, and inclusion body myositis29-31 January 1999, Naarden, The Netherlands. Müller-Felber W; Pongratz D; Reimers C Neuromuscul Disord; 2001 Jan; 11(1):88-92. PubMed ID: 11166170 [No Abstract] [Full Text] [Related]
17. Misunderstandings, misperceptions, and mistakes in the management of the inflammatory myopathies. Kissel JT Semin Neurol; 2002 Mar; 22(1):41-51. PubMed ID: 12170392 [TBL] [Abstract][Full Text] [Related]
18. [Three patients with divergent presentations of idiopathic inflammatory myopathy]. Bronner IM; van der Meulen MF; Linssen WH; Hoogendijk JE; de Visser M Ned Tijdschr Geneeskd; 2002 May; 146(18):833-8. PubMed ID: 12038218 [TBL] [Abstract][Full Text] [Related]
19. Dermatomyositis. Diagnosis and evaluation of dermatomyositis, polymyositis, and inclusion-body myositis. Krajnc I Adv Exp Med Biol; 1999; 455():181-6. PubMed ID: 10599341 [TBL] [Abstract][Full Text] [Related]
20. Inflammatory Myopathies with Cutaneous Involvement: from Diagnosis to Therapy. Dourmishev LA Folia Med (Plovdiv); 2017 Mar; 59(1):7-13. PubMed ID: 28384112 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]